Business Wire

NEXWAY

26.1.2021 14:02:08 CET | Business Wire | Press release

Share
Software Industry: Nexway™ Reinforces the Customer Experience Capabilities of its Monetize Personalized Growth Platform

Nexway , a leading software and service company for e-commerce and payments, is very excited to launch the latest features on its personalized growth platform Nexway Monetize , moving forward in its mission to expand the online footprint and sales potential of software vendors, games publishers and service providers across 140 countries around the world.

In today’s uncertain business environment, the e-commerce and payment leader is looking to leverage its best technologies to offer a seamless purchase experience, helping its clients to remain flexible in their strategic approach to e-commerce.

Nexway‘s teams are driving versatility, flexibility, and frictionless features to conquer new markets and expand into vertical sectors linked to customer monetization , subscriptions , and B2B sales management . Nexway also intends to continue growing thanks to its agility, expertise, and high level of the customer purchase experience.

"Customer experience is a constantly moving target, changing to meet customer needs, expectations, and evolution. Every customer has different needs and flexibility skills are crucial to adjust to situations and being able to effectively address such challenges. Being flexible with your customers is a top priority in the COVID-19 world ." comments Frédéric Ribau , Chief Technical Officer and Chief Product Officer at Nexway.

To meet these expectations and context, the Company has tuned its Nexway Monetize platform with new e-commerce features and payment capabilities.

NEXWAY MONETIZE NEW FEATURES RELEASED

1/ Nexway launches multiple pre-order options available right away on the Monetize platform. This feature is mostly aimed, but not limited, at gaming publishers , allowing to convert consumers before a product/game release, to create buzz, to offer exclusivity or bonuses to its community, or simply to test its product/game. Read more.

2/ Nexway announces the evolution of its subscription capabilities and launches its subscription trial extension. This feature is intended for digital product and service providers to offer consumers a subscription with a trial period, to be renewed and extended automatically into a standard paying subscription. The trial period will be a new period integrated into the subscription model, allowing the provider to define the duration of the trial period and switch it on or off depending on his will. Read more .

3/ Nexway expands its global payment services, announcing a massive regional expansion of its payment capabilities and services. Efficiently selling in different countries requires expertise and specific capabilities. Nexway Monetize simplifies commerce with powerful payment technology and helps its customers to process payments in local currencies with the most adapted payment methods worldwide.
- Monetize supports India and the Nordics countries with local currencies and regional preferred payment methods
- In addition to Brazil, Nexway reinforces its LATAM footprint
- A range of new currencies has been implemented on Nexway’s payment platform
- Payments in installments are now available in Brazil
- Nexway enables its clients to provide local offline payment methods

Read more.

4/ To help publishers to develop their reseller network and bring differentiation to its existing reseller portal offer , Nexway has developed automatic commissions on license renewals feature for resellers. The goal of this feature is to increase the loyalty of the resellers. Read more.

“Whether B2B or B2C, today’s customers have an ever-higher expectation of service. Our challenge is to optimize the experience of our customers and support them in creating a strong differentiation and competitive advantage within the digital economy. Throughout 2021, we plan to add new solutions and features to support commerce by allowing companies to expand across borders and verticals,” adds Frédéric Ribau .

Product Documentation: Nexway Monetize

Ready to enhance customer experience and boost your global sales potential! Discover Nexway Monetize: personalized e-commerce growth platform. GET STARTED NOW

ABOUT NEXWAY
Nexway SASU is a leading e-commerce and payment player. Combining technology and managed services, Nexway helps online businesses scale, grow, and thrive. Nexway’s expertise in subscriptions, local payments, fraud prevention, and reseller management enables customers to transform their purchasing experience and accelerate sales. Founded in 2002 and headquartered in Paris–La Défense, France, Nexway has subsidiaries in the USA, Brazil, Italy, Spain, Poland, and Japan. Companies that rely on Nexway include FNAC-Darty™, Amazon™, Kaspersky™, Adobe™, Avast™, TakeTwo™, and hundreds more.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye